DelMar Pharmaceuticals Inc (NASDAQ:DMPI) Expected to Post Earnings of -$0.20 Per Share

Equities research analysts predict that DelMar Pharmaceuticals Inc (NASDAQ:DMPI) will post ($0.20) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.80) in the same quarter last year, which would suggest a positive year-over-year growth rate of 75%. The company is expected to report its next earnings report on Monday, February 10th.

According to Zacks, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($1.20) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($0.90) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for DelMar Pharmaceuticals.

DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.59).

A number of equities research analysts have weighed in on the stock. Maxim Group reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Friday. Zacks Investment Research raised shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th.

Shares of DelMar Pharmaceuticals stock traded down $0.01 during trading on Friday, reaching $0.77. 471,300 shares of the company’s stock were exchanged, compared to its average volume of 713,306. The company has a market cap of $2.08 million, a P/E ratio of -0.24 and a beta of 1.30. The firm’s 50-day moving average price is $0.56 and its 200 day moving average price is $1.19. DelMar Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $6.80.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.

Recommended Story: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit